Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Date:5/9/2011

ts XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has two projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the timing of the milestone payments from Pfizer; Pfizer's ability to commercialize XIAPEX for Dupuytren's contracture in EU and Eurasian markets; the timing or likelihood of additional launches of XIAPEX in other EU and Eurasian markets and our receipt of any applicable milestone payments from Pfizer; Asahi Kasei Pharma's ability to develop, register for approval and commercialize XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan; the timing of reporting of results from the phase III trial for XIAFLEX for the treatment of Peyronie's disease; the Company's expected financial performance in 2011; products in development for Dupuytren's contracture and Frozen Shoulder syndrome; and the potential for XIAFLEX to be used in multiple indications.  


'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
6. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
8. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
9. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... LAWRENCEVILLE, N.J. , May 28, 2015 ... announced that it has received commitments from two institutional ... million of the Company,s common stock in an at-the-market ... warrants to purchase common stock. The Company ... pursuant to which the Company agreed to sell an ...
(Date:5/28/2015)... 2015 BioNorth Texas (BioNorthTX), an ... the life sciences industry in northern region of ... at The Foundry in Dallas on April 27, ... together a broad spectrum of biotech professionals from ... early successes in partnering with key life sciences ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
(Date:5/28/2015)... Fertility Centers of New England is proud to announce ... a new and expanded role as Medical Director. In ... and quality assurance for the practice. , “We are ... experienced reproductive endocrinologists,” said Fertility Centers of New England ... and compassionate, individualized care have helped set FCNE apart ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... Inc.,(NASDAQ: VSGN ; TSX:VAS), today announced that it ... its cash burn rate and focus its,efforts on ... most,likely to provide long-term shareholder value. This plan ... series of drugs while the,Company seeks alternatives to ...
... April 14 Metabolex, Inc., a,biopharmaceutical company ... new medicines for the treatment of metabolic ... joined the company as chief,financial officer. Mr. ... to Metabolex, including expertise in business,development, treasury ...
... form basis of blood-based ColonSentry(TM) test -, ... GEN),a company focused on developing blood-based biomarker tests ... management, today reported,positive performance results from a large ... assessment of a patient,s current risk for,colorectal cancer. ...
Cached Biology Technology:Vasogen Announces Implementation of Strategic Restructuring Plan 2Vasogen Announces Implementation of Strategic Restructuring Plan 3Vasogen Announces Implementation of Strategic Restructuring Plan 4Vasogen Announces Implementation of Strategic Restructuring Plan 5Metabolex Appoints Donald Hill as Chief Financial Officer 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3
(Date:5/22/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... its promotional pricing and making the Wocket generally available for ... , Head of Marketing said, "We,ve extended the opportunity to ... of May. To get your wocket at this special price, ... store on June 1, you,ll receive a unique code that ...
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... to adapt to moderate climate warming, improving their chance of ... large reductions in carbon dioxide emissions, according to a study ... its academic partners. Results further suggest corals have already adapted ... modeling work suggested that coral reefs would be gone by ...
... Recent years have seen significant outbreaks of listeriosis on ... usually be treated successfully, it is occasionally fatal, most ... when treatment is effective, the symptoms are anything but ... diarrhoea and other gastrointestinal symptoms. The old adage is ...
... is a lead partner in a new 6 million ... treat Cystic Fibrosis. Affecting more than 10,000 people ... the most common life-threatening inherited diseases. Symptoms include repeated ... The new global programme, known as CF Matters, aims ...
Cached Biology News:New study suggests coral reefs may be able to adapt to moderate climate change 2New study suggests coral reefs may be able to adapt to moderate climate change 3Passing the Gac 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 3
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
... GenBank Accession Number : ... (C-QSQENQDTRPKVKAKK), corresponding to amino acids ... Formulation: antiserum in 0.05% sodium ... Assurance: routinely evaluated by immunoblot ...
Request Info...
...
Biology Products: